Quris
Quris Technologies is a dual-headquartered (Boston and Tel Aviv) Bio-AI company that operates a clinical prediction platform combining machine learning with miniaturized patients-on-a-chip technology to forecast drug safety and efficacy for large pharmaceutical companies.
- Company typePrivate
- Founded2019
- HeadquartersTel Aviv, Israel
- Headcount11–50
- GTM typeB2B and B2C
- OfferingSoftware
What Quris does
Quris Technologies LTD is a privately held Bio-AI company, dual-headquartered in Boston and Tel Aviv, that operates the Bio-AI Clinical Prediction Platform — a system combining machine learning with miniaturized patients-on-a-chip technology to predict which drug candidates will safely work in humans before clinical trials. The platform tests thousands of compounds on stem-cell-derived organ chips equipped with proprietary nano-sensors, generating automatically-tagged training data that feeds proprietary ML classification algorithms and generative AI models; the founding team holds 48 patents and the platform is backed by 18-30 granted and pending patents. Exclusive collaboration with the New York Stem Cell Foundation enables training across genetically diverse tissues, and the October 2024 acquisition of Nortis added NCATS/NIH-vetted Kidney-on-Chip capability to the existing liver and other organ models.
Quris serves large pharmaceutical companies through enterprise licensing and collaborative research agreements, anchored by an expanded relationship with Merck KGaA (Darmstadt, Germany) covering drug-induced liver injury prediction with an option for an up-to-five-year exclusive license in a specific disease domain. Revenue mechanics combine platform licensing and royalties, collaborative development fees, and platform adoption contracts; pricing is not publicly disclosed and contracts are negotiated individually with pharma partners. Distribution is sales-led and enterprise-focused, supported by participation in AstraZeneca's BeyondBio SCALE accelerator with Accenture, AWS, and Clalit, and a dedicated qlab.quris.ai pharma portal. A consumer-facing sub-brand, Be Well, adapts the same Bio-AI platform for personalized longevity and preventive wellness, representing a secondary go-to-market beyond the pharma core.
Quris firmographics
Firmographics- Name
- Quris
- Legal name
- Quris Technologies LTD
- Website
- https://quris.ai
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Quris Technologies is a dual-headquartered (Boston and Tel Aviv) Bio-AI company that operates a clinical prediction platform combining machine learning with miniaturized patients-on-a-chip technology to forecast drug safety and efficacy for large pharmaceutical companies.
- Ownership category
- akta.pro rank
Quris industry classification
Industry- Product category
- AI Drug Safety Prediction Platform
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Analytical Laboratory Instrument Manufacturing (334516)
- SIC
- Laboratory Analytical Instruments (3826), Services-Medical Laboratories (8071)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industries
- In Silico / Computational Toxicology & PK/PD Modeling (HLAGAFAM), Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO)
Keywords
Where Quris is headquartered
LocationHeadquarters
- HQ city
- Tel Aviv
- HQ country
- Israel
- HQ region
- Middle East
Offices2 records
Markets served
Quris business model
Business model- GTM type
- B2B and B2C
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Platform Licensing: Pharmaceutical companies license the BioAI platform for drug safety prediction. Merck KGaA has option to obtain up to five-year exclusive license to specific disease domains upon exercising options.
- Collaborative Development: Collaborative research agreements with pharmaceutical companies for preclinical studies and platform assessment, with potential option fees and milestone payments.
- Platform Adoption Contracts: Strategic collaborations with investments where pharma partners gain access to Quris-AI platform for toxicity prediction, ADME modeling, and clinical optimization.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Multi-year contract | Enterprise platform licensing with undisclosed fees |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels5 records
Quris product offering
Product offeringCore offering
Quris operates the world's first Bio-AI Clinical Prediction Platform, which trains machine learning and generative AI algorithms on data generated by testing thousands of drug candidates on miniaturized, stem-cell-derived Patients-on-a-Chip with nano-sensor monitoring. The platform predicts which drug candidates will be safe and efficacious in humans, helping pharmaceutical companies reduce the 89% clinical trial failure rate. Supporting offerings include the DILI (Drug-Induced Liver Injury) Prediction Service and, via the 2024 Nortis acquisition, Kidney-on-Chip models integrated into the platform. A consumer-facing Be Well sub-brand adapts the underlying Bio-AI technology for personalized longevity and preventive health applications.
Product overview
Quris offers the Bio-AI Clinical Prediction Platform as its core product, which is the world's first AI platform that predicts which drug candidates will safely work in humans using miniaturized patients-on-a-chip technology. The platform is augmented by the DILI Prediction Service for liver toxicity assessment and was expanded through the acquisition of Nortis Kidney-on-Chip technology. A consumer-facing sub-brand called 'Be Well' adapts the same Bio-AI technology for personalized longevity and preventive health applications. The company is dual-headquartered in Boston and Tel Aviv, with the platform backed by strategic biotech and big data investors.
Differentiator
Problem solved
Functional benefit
Brands
- Bio-AI Clinical Prediction Platform: The company's core AI platform that predicts drug safety and efficacy using machine learning trained by testing drugs on miniaturized patients-on-a-chip.
Products and services
- Bio-AI Clinical Prediction Platform The world's first Bio-AI clinical prediction platform that simulates clinical trials using AI-powered miniaturized patients-on-a-chip. Trains machine learning and generative AI algorithms on automatically-tagged data generated by testing drugs on stem-cell-derived tissue models to predict which drug candidates will safely work in humans. Targets large pharmaceutical companies seeking to reduce the 89% clinical trial failure rate and decrease reliance on animal testing.
- DILI Prediction Service Drug-Induced Liver Injury (DILI) prediction service that identifies liver toxicity risks in drug candidates, including toxicity that preclinical experiments may fail to detect. Delivered via the Bio-AI Clinical Prediction Platform and accessed by pharma partners through the Quris pharma portal. Accuracy demonstrated through the Merck KGaA collaboration.
- Nortis Kidney-on-Chip Pioneering Kidney-on-Chip technology acquired from Nortis (Numa Biosciences, Inc.), previously vetted by the National Center for Advancing Translational Sciences (NCATS) under NIH. Integrated into the Bio-AI Clinical Prediction Platform to enhance drug safety predictions in pre-clinical and clinical phases for pharmaceutical customers.
- Be Well (Personalized Longevity) Consumer-facing personalized health and longevity platform adapting Quris's Bio-AI technology for individual consumers. Creates personalized stem cells (iPSCs) from blood draws, generates bio-avatars of organs (liver, heart, kidney, brain), and provides AI-powered insights for personalized medication, supplements, and wellness recommendations.
Quantifiable outcome
- 89% of drugs fail in clinical trials despite promising pre-clinical data
- +2 more outcomes
Companies that use Quris
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles2 records
Quris technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature6 records
Quris partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered core, flagship and supporting.
- Nortis (Numa Biosciences, Inc.)coreAsset acquisition of Nortis Kidney-on-Chip technology, vetted by NCATS/NIH. Quris integrating pioneering kidney technology with its Bio-AI platform. Will continue Nortis collaborations with research institutes, FDA, and pharmaceutical companies.
- Merck KGaA, Darmstadt, GermanycoreExpanded collaboration following successful preclinical study. Merck further leveraging platform to identify liver toxicity risks. Option to obtain exclusive license to specific disease domain upon exercise. Quris may receive undisclosed amount.
- AstraZeneca BeyondBio SCALE ProgramflagshipSelected as one of six startups for BeyondBio SCALE program led by AstraZeneca, Accenture, AWS, and Clalit. Nine-month program helping Israeli startups in digital health and AI navigate journey from startup to scaleup with global market focus.
- AccentureflagshipPartner in AstraZeneca BeyondBio SCALE program providing expert support for market development and solution deployment.
- AWS (Amazon Web Services)flagshipCloud infrastructure partner in AstraZeneca BeyondBio SCALE program supporting Quris with cloud services for platform deployment.
- ClalitflagshipLargest healthcare organization in Israel, partner in BeyondBio SCALE program helping startups deploy solutions in Israeli healthcare system and globally.
- Merck KGaA, Darmstadt, GermanycoreSigned agreement allowing Merck KGaA to assess Quris BioAI safety prediction platform, comparing to traditional in vitro and vivo approaches. Initial focus on liver toxicity risks. Merck has option for up to five-year exclusive license to specific disease domain.
- The New York Stem Cell Foundation (NYSCF)coreExclusive collaboration for stem-cell automation technology. NYSCF is world leader in stem-cell automation. Collaboration enables Quris to train AI platform on hundreds of genetically diverse stem cell-derived patients-on-a-chip.
- The Hebrew University of JerusalemsupportingResearch partner in Quris ecosystem. Part of academic network supporting Bio-AI platform development.
- Tel Aviv UniversitysupportingResearch partner in Quris ecosystem. Academic collaboration for platform development and research.
- NewStemsupportingTechnology partner in Quris ecosystem. Part of partner network supporting Bio-AI platform capabilities.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
Quris competitors and assessment
Company assessmentDirect peers
- Recursion Pharmaceuticals: Recursion is an AI-driven drug discovery platform combining high-throughput wet-lab biology with machine learning to identify novel therapeutics. Directly comparable to Quris in its mission to use ML to compress preclinical timelines and improve clinical translation, and cited by Quris itself as a peer.
- Insitro: Insitro uses ML on large-scale biological data (including patient-derived cells) to discover and develop therapeutics. Closely comparable to Quris in combining wet-lab biology, ML, and pharma partnerships, with a similar enterprise GTM targeting large pharma R&D organizations.
- Atomwise: Atomwise applies AI (AtomNet) to small-molecule drug discovery and partners with pharma on hit identification and optimization. Direct peer in AI-for-pharma with established multi-pharma partnership model, though more virtual-screening focused than Quris's wet-lab approach.
- Verge Genomics: Verge uses ML on human patient tissue datasets to identify drug targets and develop therapeutics in neuroscience. Comparable to Quris in its use of ML trained on proprietary human-derived biological data, though focused on a narrower therapeutic area.
- XtalPi: XtalPi combines AI, quantum physics, and large-scale computation with robotic labs to accelerate drug discovery and development. Direct peer to Quris in the AI-pharma platform category and explicitly named by Quris as a benchmark.
- Emulate, Inc. Emulate is a leading organ-on-chip company whose Liver-Chip and other organ-chip products are used by pharma for preclinical safety and efficacy testing. Closely comparable to Quris's patient-on-chip technology layer, though Emulate focuses on instruments and assays rather than the AI prediction layer.
- CN Bio Innovations: CN Bio develops organ-on-chip microphysiological systems (Liver, Lung, Gut) sold to pharma and research institutes for drug safety and efficacy testing. Direct peer to Quris's chip-on-chip platform at the wet-lab technology layer with overlapping pharma customer base.
- Mimetas: Mimetas develops organ-on-a-chip and tissue models (OrganoPlate) used in pharma R&D for toxicity and disease modeling. Direct technology peer to Quris's patient-on-chip platform and serves overlapping pharma R&D buyers.
Broad incumbents
- Schrödinger, Inc. Schrödinger provides computational chemistry and physics-based software platforms (LiveDesign) for drug discovery used broadly by large pharma. Broader incumbent in AI/pharma R&D tooling; less directly competing with Quris's wet-lab focus but competing for pharma platform budgets.
Emerging players
- Owkin: Owkin applies federated ML to clinical and biological data to accelerate drug discovery and development, with pharma partnerships across multiple therapeutic areas. Emerging player with partial overlap to Quris's AI-for-pharma thesis, though focused more on patient-data ML than wet-lab organ-on-chip.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Quris social profiles
Digital presenceQuris financial estimates
Financial estimateRevenue estimate
Valuation estimate
Quris leadership team
Management profileNumber of profiles
Profiles12 records
Quris subsidiaries and ownership
Company hierarchySubsidiaries1 record
Quris funding detail
Funding detailFunding overview
Funding rounds3 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Quris M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Quris
What does Quris do?
Quris operates the world's first Bio-AI Clinical Prediction Platform, which trains machine learning and generative AI algorithms on data generated by testing thousands of drug candidates on miniaturized, stem-cell-derived Patients-on-a-Chip with nano-sensor monitoring. The platform predicts which drug candidates will be safe and efficacious in humans, helping pharmaceutical companies reduce the 89% clinical trial failure rate. Supporting offerings include the DILI (Drug-Induced Liver Injury) Prediction Service and, via the 2024 Nortis acquisition, Kidney-on-Chip models integrated into the platform. A consumer-facing Be Well sub-brand adapts the underlying Bio-AI technology for personalized longevity and preventive health applications.
Is Quris a public or private company?
Quris is a private company. It is classified as venture growth investor backed and is currently operating.
When was Quris founded?
Quris was founded in 2019. It employs 11 to 50 people.
Where is Quris based?
Quris is headquartered in Tel Aviv, Israel, in the Middle East region.
How does Quris make money?
Three revenue lines are on record. Platform Licensing is the primary driver. The others are collaborative Development and platform Adoption Contracts.
Who are Quris's main competitors?
Direct peers on record are Recursion Pharmaceuticals, Insitro, Atomwise, Verge Genomics, XtalPi, Emulate, Inc., CN Bio Innovations and Mimetas. Schrödinger, Inc. is listed as a broad incumbent. Owkin is listed as an emerging player.
Does Quris have an API?
No public API is recorded for Quris.
What industry is Quris in?
Quris's product category is AI Drug Safety Prediction Platform. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAGAFAM, In Silico / Computational Toxicology & PK/PD Modeling. Its NAICS code is 541714 and its SIC code is 3826.